Log in to the research portal to view current pricing, stock, and bundles and order.
Fat Loss & Weight Management research peptides in this catalog
Why the Incretin System Anchors This Research Class
Much of the metabolic research interest in this category traces back to the incretin system, a set of gut-derived signaling pathways that the body uses to coordinate nutrient intake with hormone release. When nutrients reach the small intestine, specialized enteroendocrine cells secrete incretin hormones, principally glucagon-like peptide-1 (GLP-1) from L-cells and glucose-dependent insulinotropic polypeptide (GIP) from K-cells. These hormones act as messengers that prime the pancreas and central nervous system before blood glucose rises sharply, a phenomenon documented in decades of physiology literature as the incretin effect.
Researchers study GLP-1 and GIP receptor agonist peptides because they engage these same receptors. The scientific value lies in modeling how sustained receptor engagement alters insulin secretion dynamics, gastric motility, and central appetite circuitry in cell cultures and animal models. The peptides in this category are tools for probing those mechanisms, not products that act on any person.
Pancreatic Beta Cells, Insulin Secretion, and Glucose-Dependence
A defining feature of incretin biology, and a frequent subject of in-vitro investigation, is glucose-dependence. GLP-1 receptor activation on pancreatic beta cells amplifies insulin secretion only when glucose concentrations are elevated. In isolated islet preparations, researchers observe that GLP-1 receptor agonists potentiate glucose-stimulated insulin release through cyclic AMP signaling and enhanced calcium influx, while having minimal effect at low glucose. This glucose-dependence is a key reason the class is studied as a model of tightly regulated secretagogue activity.
Beyond acute secretion, the research literature examines effects on beta-cell gene expression, proliferation markers, and resistance to apoptosis in cultured cells. GIP receptor signaling adds another layer, with reported roles in both insulin secretion and adipocyte lipid handling. Studying single versus dual receptor engagement lets researchers separate these contributions experimentally.
Single GLP-1 Agonism: Semaglutide as a Research Model
Semaglutide is studied as a long-acting GLP-1 receptor agonist. Its structure is engineered for metabolic stability and albumin binding, extending its half-life relative to native GLP-1, which is degraded within minutes by the enzyme dipeptidyl peptidase-4. In research models, this stability allows investigators to study sustained single-receptor activation across pancreatic, gastrointestinal, and hypothalamic tissues.
The scientific literature describes GLP-1 receptor agonism slowing gastric emptying and engaging satiety-related neurons in the hypothalamus and brainstem. Semaglutide also has an approved pharmaceutical form as a prescription drug product. The material offered here is not that drug product; it is research-grade compound for laboratory and in-vitro study only, and is not for human or animal consumption.
Dual GLP-1/GIP Agonism: Tirzepatide and Receptor Combination Research
Tirzepatide is studied as a dual agonist that engages both the GLP-1 and GIP receptors with a single peptide. This makes it a valuable research tool for investigating whether co-activating two incretin pathways produces effects distinct from GLP-1 activation alone. In preclinical and clinical research literature, dual agonism has been examined for its combined influence on insulin secretion, glucagon dynamics, and adipose tissue metabolism.
The GIP component is the differentiator researchers focus on. GIP receptors are expressed in adipose tissue, bone, and the brain, and the scientific debate over how GIP receptor engagement contributes to metabolic outcomes is an active area of study. Comparing Semaglutide and Tirzepatide side by side in controlled models lets investigators isolate the marginal contribution of the GIP arm. Like Semaglutide, Tirzepatide has an approved pharmaceutical form; the research-grade material here is research use only, not a drug product, and not for consumption.
Non-Incretin Lipolysis Research: AOD 9604
AOD 9604 sits outside the incretin framework entirely, which is why it appears in this category as a contrasting research model. It is a synthetic fragment corresponding to the C-terminal region of human growth hormone, specifically the segment associated with growth hormone's lipolytic activity, without the full hormone's effects on growth or insulin-like growth factor signaling. Researchers study it to probe how a short HGH fragment may influence fat metabolism independently of classical incretin receptors.
The mechanistic literature on this fragment examines lipolysis, the breakdown of stored triglycerides in adipocytes, and references the beta-3 adrenergic pathway, a signaling route involved in mobilizing fat from adipose tissue and in metabolic rate regulation in some models. Studying AOD 9604 alongside the incretin agonists gives researchers a way to compare receptor-mediated appetite and insulin pathways against a more direct adipocyte-focused mechanism. It is a research compound only, not for human or animal consumption.
Visceral Adipose and GHRH Analog Research: Tesamorelin
Tesamorelin represents yet another mechanistic angle: it is studied as a stabilized analog of growth hormone-releasing hormone (GHRH). Rather than acting on incretin receptors or directly on adipocytes, GHRH analogs engage receptors in the anterior pituitary, where they are studied for stimulating the pulsatile release of endogenous growth hormone. This places Tesamorelin in a distinct upstream position within metabolic research.
The research literature on GHRH analogs gives particular attention to visceral adipose tissue, the metabolically active fat surrounding internal organs that differs biologically from subcutaneous fat. Studies have examined how restoring growth hormone axis signaling relates to visceral fat dynamics and lipid profiles in various models. For researchers, Tesamorelin offers a tool to study the GHRH-pituitary-growth hormone axis specifically. It is research-use-only material, not for consumption.
Research Application Areas Across the Class
Taken together, these four compounds let laboratories model metabolism from several independent entry points: gut incretin signaling (Semaglutide, Tirzepatide), direct adipocyte lipolysis (AOD 9604), and the pituitary growth hormone axis (Tesamorelin). This breadth is what makes the category useful for comparative mechanistic research rather than any single application.
Common research themes in the published literature include glucose-stimulated insulin secretion assays, receptor binding and signaling studies, gastric motility models, hypothalamic satiety-circuit investigations, adipocyte differentiation and lipid mobilization assays, and characterization of enzymatic stability against DPP-4 degradation. All such work is conducted in vitro or in animal models under appropriate institutional oversight.
Research application areas
Choosing a compound for your research
Choose Semaglutide when the research question targets single GLP-1 receptor agonism in isolation, providing a clean baseline for incretin pathway studies without GIP confounding.
Choose Tirzepatide when the goal is to study dual GLP-1/GIP co-agonism and to isolate the marginal contribution of the GIP receptor arm against a GLP-1-only comparator.
Choose AOD 9604 when the investigation concerns direct adipocyte lipolysis and HGH-fragment biology rather than receptor-mediated appetite or insulin signaling.
Choose Tesamorelin when the research focuses upstream on the GHRH-pituitary-growth hormone axis and visceral adipose tissue dynamics rather than gut incretin pathways.
Pair an incretin agonist with AOD 9604 or Tesamorelin in comparative study designs to contrast receptor-mediated mechanisms against direct lipolytic or pituitary-axis mechanisms.
Confirm purity, sequence identity, and DPP-4 stability data for any incretin peptide before designing assays, since degradation kinetics differ substantially across this class.
Per-compound reference data: Semaglutide reference · Tirzepatide reference · AOD 9604 reference · Tesamorelin reference.
Frequently asked questions
What distinguishes Semaglutide from Tirzepatide in research terms?
Semaglutide is studied as a single GLP-1 receptor agonist, while Tirzepatide is studied as a dual agonist engaging both GLP-1 and GIP receptors. The scientific distinction matters because GIP receptors are expressed in adipose tissue, bone, and brain, so dual agonism lets researchers investigate whether co-activating two incretin pathways produces effects distinct from GLP-1 activation alone. Comparing the two in controlled models isolates the contribution of the GIP arm.
How does AOD 9604 differ mechanistically from the incretin peptides?
AOD 9604 is a synthetic fragment of human growth hormone corresponding to the region associated with lipolytic activity, and it sits entirely outside the incretin framework. Rather than engaging GLP-1 or GIP receptors, it is studied for influencing adipocyte fat breakdown, with reference to the beta-3 adrenergic pathway. This makes it a contrasting research model for fat metabolism independent of gut-derived incretin signaling and insulin secretion pathways.
What is the role of GHRH analogs like Tesamorelin in metabolic research?
Tesamorelin is studied as a stabilized analog of growth hormone-releasing hormone. It engages receptors in the anterior pituitary, where it is investigated for stimulating pulsatile endogenous growth hormone release. This positions it upstream of both incretin and direct adipocyte pathways. Research literature gives particular attention to visceral adipose tissue, the metabolically active fat surrounding internal organs, and to the GHRH-pituitary-growth hormone axis in model systems.
Why is glucose-dependence emphasized in incretin research?
Glucose-dependence is a defining feature studied in this class. In isolated islet and beta-cell preparations, GLP-1 receptor agonists amplify insulin secretion mainly when glucose concentrations are elevated, with minimal effect at low glucose. This is mediated through cyclic AMP signaling and enhanced calcium influx. Researchers emphasize it because it characterizes the class as a tightly regulated secretagogue model, important for understanding beta-cell biology and glucose handling.
Are these compounds the same as approved pharmaceutical products?
Semaglutide and Tirzepatide have approved pharmaceutical forms that exist as regulated prescription drug products. However, the material listed in this category is research-grade compound intended strictly for laboratory and in-vitro research use only. It is not a drug product, is not manufactured or supplied as a medicine, and is not for human or animal consumption. The distinction between research-grade material and an approved drug product is important and absolute.
How should research-grade peptides in this category be reconstituted and stored?
Most of these peptides ship as lyophilized powder and are reconstituted in a laboratory using an appropriate sterile diluent such as bacteriostatic or sterile water, following established protocols. Lyophilized material is generally stored frozen and protected from light, while reconstituted solutions are typically refrigerated and used within a limited window. Researchers should verify certificate-of-analysis purity and sequence identity, and handle all material under proper laboratory conditions, for research use only.
Create a free research account to view current pricing, real-time stock, and bundle options, then submit your order for approval.
Related: What are peptides? · Reference library · Cost & pricing · Price comparison · Research guides · Order portal